Core Viewpoint - The stock of Gilead Sciences-B (01672) rose over 5% following the announcement of positive results from its ASC30 oral GLP-1R agonist study, indicating significant weight loss and good safety profile [1] Company Summary - Gilead Sciences reported a 5.02% increase in stock price, reaching HKD 10.88, with a trading volume of HKD 92.59 million [1] - The company announced results from a 28-day multiple ascending dose study of ASC30, showing a maximum average weight loss of 6.5% compared to baseline after treatment [1] - ASC30 demonstrated superior efficacy due to higher oral drug exposure, with good safety and tolerability, experiencing only mild to moderate gastrointestinal adverse events [1] Industry Summary - Dongwu Securities highlighted that Gilead Sciences has several catalysts in the second half of the year, with multiple important clinical data releases expected [1] - The firm anticipates that by Q4 2025, Gilead will report top-line data for ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I trials, with ASC30 subcutaneous Phase II data expected in Q1 2026 [1] - The company plans to submit 2-3 new IND applications to the FDA within the next 6-9 months, including a dual-target peptide weight loss pipeline [1]
港股异动 | 歌礼制药-B(01672)涨超5% ASC30展现优越疗效及安全性数据 公司下半年催化剂较多